1. Scrip
  2. >>Business

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

 
• By Emily Hayes

Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

Emerging Company Profile Regular column feature image Version 2

Big pharma didn't get anywhere with corticotropin releasing factor-receptor 1 (CRF-R1) antagonism in broad psychiatric conditions like depression and anxiety, but like its San Diego peer Neurocrine Biosciences Inc., privately-held San Francisco start-up Spruce Biosciences sees a role now for the small molecule class in treating a condition called congenital adrenal hyperplasia (CAH).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.